Company / Free Cash Flow per Share
Xenon Pharmaceuticals Inc. Free Cash Flow per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow per Share
-$3.53
FY2025
5-year range
-$3.53 / -$1.64
FY2021-FY2025
Trend
-49.1%
vs FY2024
Sector context
#160 of 192
Health Care
What the data says
Xenon Pharmaceuticals Inc.'s free cash flow per share of $-3.53 is lower than 83% of companies in the Health Care sector (FY2025). Free Cash Flow per Share has declined for 6 consecutive years, from $-0.23 in FY2019 to $-3.53 in FY2025.
Based on SEC 10-K filings.
-3.53 in FY2025.
Declined from $-2.34 to $-3.53 over the past 2 years.
Health Care sector context is included.
Free Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 17% in Health CareTop 83% of 192This company -$3.53 Sector average -$19.84
▼
+82.2% above sector average
Key checks
Key Insights
- Xenon Pharmaceuticals Inc.'s free cash flow per share has declined for 6 consecutive years.
- In FY2025, free cash flow per share decreased 49.1% year-over-year.
- Ranks #160 out of 192 companies in the Health Care sector.
- Peak free cash flow per share was recorded in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 3.51 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$3.53 | -49.1% |
| FY2024 | -$2.37 | -1.1% |
| FY2023 | -$2.34 | -36.5% |
| FY2022 | -$1.72 | -4.7% |
| FY2021 | -$1.64 | -11.6% |
| FY2020 | -$1.47 | -540.2% |
| FY2019 | -$0.23 | +88.3% |
| FY2018 | -$1.96 | -88.2% |
| FY2017 | -$1.04 | +24.6% |
| FY2016 | -$1.38 | -4.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026